Basel, Switzerland — February 20, 2026: Roche announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for giredestrant, an investigational oral selective oestrogen receptor degrader (SERD), in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following progression on prior endocrine therapy. The filing acceptance, supported by pivotal Phase III evERA trial data, sets a Prescription Drug User Fee Act (PDUFA) decision date of 18 December 2026, positioning the regimen as a potential first-in-class oral SERD combination in the post-CDK4/6 inhibitor setting.
Science Significance
The NDA acceptance is underpinned by robust results from the Phase III evERA Breast Cancer study, where giredestrant plus everolimus demonstrated statistically significant improvements in progression-free survival (PFS) compared with standard endocrine therapy plus everolimus. The combination reduced the risk of disease progression or death by 44% in the intention-to-treat population and by a striking 62% in patients with ESR1 mutations, a subgroup known for endocrine resistance. Median PFS reached 9.99 months versus 5.45 months in ESR1-mutated patients, underscoring the therapy’s targeted mechanistic advantage. As a next-generation oral SERD, giredestrant works by binding to and degrading the oestrogen receptor, thereby inhibiting tumour growth signalling pathways central to hormone-driven breast cancer biology.
Regulatory Significance
The FDA’s acceptance of the NDA marks a critical regulatory milestone and validates the strength of the evERA clinical dataset. With a confirmed PDUFA action date of 18 December 2026, the application enters formal review, bringing the therapy closer to potential U.S. approval. If cleared, the regimen could become the first and only all-oral SERD combination approved after CDK4/6 inhibitor therapy, addressing a major treatment gap. Regulatory submissions based on evERA data are also planned or underway with additional global health authorities, indicating a coordinated international filing strategy aimed at accelerating patient access worldwide.
Business Significance
Advertisement
From a commercial standpoint, the filing strengthens Roche’s oncology pipeline and reinforces its long-term investment in hormone receptor-positive breast cancer therapeutics. ER-positive disease accounts for approximately 70% of all breast cancer cases, representing a substantial global market opportunity. The potential approval of giredestrant could expand Roche’s endocrine therapy franchise while complementing its targeted oncology portfolio. Continued development across multiple Phase III trials — including early-stage and first-line metastatic settings — signals lifecycle expansion strategies that could drive sustained revenue growth and competitive positioning in the endocrine oncology segment.
Patients’ Significance
For patients, the investigational combination offers the promise of a new oral treatment option designed to overcome endocrine resistance, a leading cause of disease progression in advanced ER-positive breast cancer. Resistance following CDK4/6 inhibitor therapy is associated with poorer outcomes and limited therapeutic alternatives. By targeting the oestrogen receptor for degradation while simultaneously inhibiting mTOR signalling via everolimus, the regimen introduces a dual-pathway blockade strategy. Importantly, an all-oral regimen may reduce treatment burden by eliminating injections, potentially improving treatment adherence, quality of life, and long-term disease management.
Policy Significance
The NDA acceptance also reflects broader regulatory and policy momentum toward precision oncology and biomarker-driven drug development. ESR1 mutations represent a clinically actionable resistance mechanism, and therapies designed for molecularly defined populations align with evolving FDA priorities around targeted medicine. Approval could influence future treatment guidelines, reimbursement frameworks, and diagnostic testing policies, particularly regarding routine ESR1 mutation screening. Additionally, the development reinforces policy support for expedited oncology pathways that address high unmet medical needs.
Roche’s regulatory progress with giredestrant marks a significant advance in the evolving endocrine therapy landscape. Backed by compelling Phase III efficacy data and a clear biomarker rationale, the investigational SERD combination has the potential to redefine post-CDK4/6 treatment standards in advanced breast cancer. As the FDA review advances toward its December 2026 decision deadline, stakeholders across clinical, regulatory, and commercial sectors will be closely monitoring whether this targeted oral combination can emerge as a new standard of care for patients facing endocrine-resistant disease.
Source: Roche press release
